학술논문
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
Document Type
Journal Article
Author
Akifumi Kuwano; Akihiro Ueda; Aritsune Ooho; Kenta Motomura; Kohsuke Tanaka; Koutarou Uchimura; Liver Disease Investigators' Network of Kyushu University & Surrounding Hospitals (LINKS); Mai Nakashima; Makoto Nakamuta; Mari Ooe; Masami Kuniyoshi; Masatake Tanaka; Masayoshi Yada; Motoyuki Kohjima; Naoki Yamashita; Nobito Higuchi; Rie Sugimoto; Seiya Tada; Shigehiro Nagasawa; Shigeru Harada; Taiji Mutsuki; Takeaki Satoh; Takeshi Senju; Tomonobu Hioki; Toshimasa Koyanagi; Tsukasa Nakamura; Tsuyoshi Yoshimoto; Yoshifusa Aratake; Yuki Tanaka; Yuusuke Morita
Source
Internal Medicine. 2022, 61(21):3157
Subject
Language
English
ISSN
0918-2918
1349-7235
1349-7235
Abstract
Results The median albumin-bilirubin (ALBI) value showed little change during ramucirumab treatment. The ALBI value improved in 32% of patients, and their prognoses were better than in those who did not improve. Response and efficacy rates were not as high as those in the REACH-2 study but were similar when limited to patients with 2,500 ng/mL AFP. Thirteen patients received further treatment after ramucirumab failure and they had a significantly better prognosis from ramucirumab administration and also had a significantly better prognosis from the start of the first tyrosine kinase inhibitor than who did not received further treatment. In univariate and multivariate analyses of prognostic factors, the continuation of treatment with another drug after ramucirumab failure and a good ALBI value at initiation were significant. The presence of a ramucirumab response and treatment duration were not associated with the prognosis. A good ALBI value at initiation and ALBI value improvement during treatment were also identified as independent factors associated with eligibility for further treatment after ramucirumab failure. The treatment line did not correlate with the availability of treatment with another drug after treatment failure.